{
  "id": "61f59592882a024a10000010",
  "type": "yesno",
  "question": "Is Sotrovimab effective for COVID-19?",
  "ideal_answer": "Yes. Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34531332",
    "http://www.ncbi.nlm.nih.gov/pubmed/34819468",
    "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
    "http://www.ncbi.nlm.nih.gov/pubmed/34556486"
  ],
  "snippets": [
    {
      "text": "It seems that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34531332",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Food and Drug Administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate COVID-19 in patients at increased risk for progression to severe illness.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819468",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Food and Drug Administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate COVID-19 in patients at increased risk for progression to severe illness.Sotrovimab is a monoclonal antibody that works directly against the spike protein of SARS-CoV-2 to block its attachment and entry into a human cell.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819468",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In patients with non-severe covid-19, casirivimab-imdevimab probably reduces hospitalisation; bamlanivimab-etesevimab, bamlanivimab, and sotrovimab may reduce hospitalisation. Convalescen",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34556486",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ms that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients. Clini",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34531332",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The Food and Drug Administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate COVID-19 in patients at increased risk for progression to severe illness",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819468",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}